BDBM350718 US10208081, Example 26
SMILES: CC[C@H]1C[C@H]2[C@@H]3CC[C@H]([C@H](C)CCN(C)C(=O)NS(=O)(=O)c4ccc(cc4)C(C)(C)C)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12
InChI Key: InChIKey=XYUDNGANLZFVHE-ASSXYKMJSA-N
Data: 1 EC50
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bile acid receptor (Homo sapiens (Human)) | BDBM350718![]() (US10208081, Example 26) | PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet ![]() | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 550 | n/a | n/a | n/a | n/a |
Enanta Pharmaceuticals, Inc. US Patent | Assay Description The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express k... | US Patent US10208081 (2019) BindingDB Entry DOI: 10.7270/Q2PV6NH9 | |||||||||||
More data for this Ligand-Target Pair |